Slide 1


The chemistry of better medicines



Fluorinov Pharmaceuticals


Non-Confidential Overview of Lead Programs

January, 2016



This presentation may contain forward-looking statements, which reflect Fluorinov's/ Trillium's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, Fluorinov's/ Trillium's ability to obtain financing to advance the products in its development portfolio; changing market conditions; the successful and timely completion of pre-clinical and clinical studies; the establishment of corporate alliances; the impact of competitive products and pricing; new product development risks; uncertainties related to the regulatory approval process or the ability to obtain drug product in sufficient quantity or at standards acceptable to health regulatory authorities to complete clinical trials or to meet commercial demand; and other risks detailed from time to time in Trillium's ongoing quarterly and annual reporting. Except as required by applicable securities laws, Fluorinov/ Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


The Art: Selective application of powerful new chemistry


Good drugs miss their potential because of chemical liabilities


Promising efficacy


Fluorinov's

seasoned chemists identify and address liabilities


FLUORINE BENEFITS


ADME/PK

Potency Stability Toxicity Oral/BBB


Drug properties separate breakthroughs from

Superior Drugs

clinical failures Lower Clinical Risk



Creating Differentiated New Medicines with Fluorine



Improve Drug Metabolism Profiles

Metabolism

  • Reduce toxic metabolites

    Marketed drug s & preclinical candidates

  • Increase active metabolites

  • Improve therapeutic window


    Increase Half-life & Lipophilicity Fluorinov's Innovative Fluorine Technology

  • Improve efficacy

    Potential for

    Toxic metabolites

  • Reduce drug dose & frequency

    X

    Metabolism

  • Improve BBB


    Enhance Bioavailability & Exposure Novel drug candidates

  • Reduce first-pass metabolism

  • Reduced dosing frequency

  • Enhance drug delivery


Trillium Therapeutics Inc. issued this content on 27 January 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 27 January 2016 14:05:06 UTC

Original Document: http://s2.q4cdn.com/772010778/files/doc_presentations/Fluorinov's-Lead-Programs.pdf